Global Leading Market Research Publisher QYResearch announces the release of its latest report “Henagliflozin Proline Tablets – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.
The global diabetes pandemic continues its relentless expansion—the International Diabetes Federation reports that approximately 540 million adults now live with the disease—while the clinical treatment paradigm has undergone a fundamental transformation. SGLT-2 inhibitors have ascended from niche oral hypoglycemic agents to cornerstone therapies delivering proven cardiorenal protection that extends far beyond glucose control. For Chinese patients and healthcare systems, this pharmacotherapeutic revolution has been complicated by a persistent reality: the SGLT-2 inhibitor market has been dominated by multinational originator products priced at significant premiums. Henagliflozin Proline Tablets, the first domestically developed oral SGLT-2 inhibitor in China, has emerged to reshape this competitive landscape—offering comparable mechanism-driven efficacy and cardiorenal benefits at a cost structure enabling broader population-level access. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Henagliflozin Proline Tablets market, examining how this domestic SGLT-2 inhibitor, oral diabetes medication, and cardiorenal protection therapy is positioned within the rapidly evolving landscape of metabolic disease management.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6700006/henagliflozin-proline-tablets
The global market for Henagliflozin Proline Tablets was estimated to be worth USD 139 million in 2025 and is projected to reach USD 479 million by 2032, advancing at a robust CAGR of 14.9% from 2026 to 2032. In 2025, global production reached approximately 120 million bottles—a volume reflecting the molecule’s transition from initial launch to broad formulary adoption across China’s public hospital system. This growth trajectory, outpacing the broader SGLT-2 class average, signals the market’s recognition of a domestic innovative drug that matches international standards while wielding compelling pharmacoeconomic advantages.
Mechanism of Action and Clinical Positioning
Henagliflozin Proline Tablets are a sodium-glucose cotransporter 2 (SGLT-2) inhibitor. By selectively inhibiting SGLT-2 in the proximal renal tubule, they block glucose reabsorption, allowing excess blood glucose to be excreted directly through the urine via an insulin-independent mechanism. This insulin-independent hypoglycemic effect distinguishes SGLT-2 inhibitors from insulin secretagogues and exogenous insulin: the glucose-lowering efficacy is proportional to filtered glucose load, intrinsically limiting hypoglycemia risk while enabling combination with any other antidiabetic agent regardless of mechanism.
Beyond glycemic control, the SGLT-2 inhibitor class has demonstrated transformative cardiorenal benefits validated across landmark cardiovascular outcome trials. Empagliflozin, dapagliflozin, and canagliflozin have each shown statistically significant reductions in hospitalization for heart failure and progression of chronic kidney disease—benefits now recognized in major international treatment guidelines as class effects applicable to SGLT-2 inhibitors as a whole. This type 2 diabetes treatment is characterized by an insulin-independent hypoglycemic effect, clear cardiovascular outcome benefits, and positive regulatory effects on body weight (through caloric loss via glycosuria) and blood pressure (through mild osmotic diuresis). The drug can be used as monotherapy or in combination with other antidiabetic agents including metformin, sulfonylureas, DPP-4 inhibitors, and insulin. It is suitable for the daily management of type 2 diabetes in adults, providing a novel and well-tolerated oral hypoglycemic option for clinical practice.
Industry Segmentation: Comparing SGLT-2 Deployment Across Metabolic, Cardiac, and Renal Indications
An exclusive analytical perspective distinguishes between three deployment contexts for Henagliflozin—pure diabetes management, heart failure treatment regardless of diabetic status, and chronic kidney disease modification—a segmentation that shapes both clinical development strategy and commercial trajectory.
Type 2 diabetes mellitus remains the foundational and largest-volume indication. Within this segment, Henagliflozin serves dual roles: as add-on therapy for patients inadequately controlled on metformin monotherapy, and as an alternative first-line agent for patients intolerant of or contraindicated to metformin. The domestic oral hypoglycemic drug advantage in this segment derives from medical insurance coverage enabling broad formulary access, a safety profile consistent with the SGLT-2 class, and pricing that reduces per-patient-year treatment costs relative to imported alternatives.
Heart failure with reduced ejection fraction (HFrEF) represents the highest-value indication expansion. SGLT-2 inhibitors are now Class I guideline-recommended therapies within the foundational quadruple therapy for HFrEF, alongside beta-blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitors. The extension of Henagliflozin’s label into heart failure—following the precedent established by dapagliflozin’s DAPA-HF and empagliflozin’s EMPEROR-Reduced trials—opens a substantial addressable population: an estimated 6.5 million heart failure patients in China alone, of whom approximately half have reduced ejection fraction.
Chronic kidney disease (CKD) represents the third strategic indication domain. The DAPA-CKD trial demonstrated that dapagliflozin reduced the composite risk of sustained eGFR decline, end-stage kidney disease, or renal death by 39% in CKD patients regardless of diabetes status. This finding established SGLT-2 inhibitors as foundational CKD therapies, expanding the addressable population beyond the approximately 140 million Chinese adults with diabetes to the substantially larger population with proteinuric CKD from any cause. Cardiorenal protection across both diabetic and non-diabetic populations represents the most significant addressable market expansion for the SGLT-2 class and, by extension, for Henagliflozin.
Competitive Dynamics: Domestic Innovation vs. Multinational Incumbency
At present, SGLT-2 inhibitors have become core medications for the management of type 2 diabetes due to their unique insulin-independent mechanism, reliable glucose-lowering efficacy, and dual cardiorenal benefits. The diabetes drug market in China remains structurally competitive: while the market is still led in value terms by international originator brands—dapagliflozin (AstraZeneca), empagliflozin (Boehringer Ingelheim), and canagliflozin (Johnson & Johnson)—domestic innovative drugs and generics are rapidly gaining volume share.
Relying on its advantages as a local innovative product, support from medical insurance coverage through National Reimbursement Drug List (NRDL) inclusion, favorable safety profile differentiating it from earlier SGLT-2 inhibitors with respect to specific adverse events, and proven compatibility in combination therapies, Henagliflozin has achieved rapid penetration in the domestic market. Growth has been particularly strong in public medical institutions, where procurement is governed by centralized volume-based procurement (VBP) tendering that favors competitively priced domestic products meeting quality and bioequivalence standards. Going forward, its SGLT-2 inhibitor market potential is expected to keep expanding as indications are extended to heart failure and chronic kidney disease, fixed-dose combination preparations are launched (pairing Henagliflozin with metformin), and overseas registration progresses through regulatory filings in emerging markets.
Competitive Landscape and Market Segments
Key players analyzed in this report include Jiangsu Hengrui Pharmaceutical as the originator and sole commercial manufacturer.
Segment by Type
- 5 mg: Lower dosage strength applicable for treatment initiation in patients with mild to moderate renal impairment or those receiving concomitant medications that may predispose to volume depletion.
- 10 mg: Standard therapeutic dosage strength for the majority of adult type 2 diabetes patients with adequate renal function.
Segment by Application
- Type 2 Diabetes Mellitus: The foundational and currently largest-volume indication driving market revenue.
- Heart Failure: High-growth indication expansion representing a patient population distinct from and additive to the diabetes market.
- Chronic Kidney Disease: Strategic indication domain with the largest potential addressable population, spanning both diabetic and non-diabetic CKD.
- Others: Encompassing potential future indications in obesity-related metabolic disorders and non-alcoholic fatty liver disease.
Strategic Outlook
Overall, Henagliflozin is on a development path characterized by breakthroughs of domestic innovation, indication-driven growth, and dual drivers of medical insurance coverage and clinical guideline endorsement. Meanwhile, the product faces intense competition from international pharmaceutical giants with established brand recognition and clinical trial datasets, domestic generics entering upon patent expiry, and new classes of hypoglycemic agents including dual GIP/GLP-1 receptor agonists that may compete for positioning in the type 2 diabetes treatment algorithm. The Henagliflozin Proline Tablets market at USD 139 million in 2025 projects to reach USD 479 million by 2032—a growth trajectory reflecting both the structural expansion of SGLT-2 inhibitor utilization and the domestic pharmaceutical innovation that now enables Chinese patients to access world-class therapy at China-appropriate pricing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
